NEUROLOGY 2000 AND BEYOND*

1 McShane R J Keene Gedling K Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997; 314:266-70.

2 Qizilbash N A Whitehead Higgins J Cholinesterase inhibition for Alzheimer’s disease: a meta-analysis of the tacrine trials. Dementia Trialists’ Collaboration. JAMA 1998; 280:1777-82.

3 Lovestone S N Graham Howard R. Guidelines on drug treatments for Alzheimer’s disease. Lancet 1997; 350:232-3.

4 Kroenke K Mangelsdorff AD. Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. Am J Med 1989; 86:262-6.

5 Carson AJ B Ringbauer Stone J Do medically unexplained symptoms matter? A prospective cohort study of 300 new referrals to neurology outpatient clinics. J Neurol Neurosurg Psychiatry 2000; 68:207-10.

6 Carson AJ B Ringbauer MacKenzie L Neurological disease, emotional disorder, and disability: they are related: a study of 300 consecutive new referrals to a neurology outpatient department. J Neurol Neurosurg Psychiatry 2000; 68:202-6.

7 Coles AJ MG Wing Molyneux P Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46:296-304.

8Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352:1498-504.

9 Jacobs LD DL Cookfair Rudick RA Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [published erratum appears in Ann Neurol 1996; 40(3):480]. Ann Neurol 1996; 39:285-94.

10Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352:1491-7.

11 Paty DW Interferon SPMS Beta 1A Study Group. Results of the 3 year double-blind, placebo-controlled study of interferon beta 1A (Rebif) in secondary progressive MS. J Neurol 1999; 246:1-15.

12ABN Council. Guidelines for the use of beta interferons in multiple sclerosis. Association of British Neurologists 1999, Ormond House, 27 Boswell Street, London WC1N 3JZ.

13 Palace J Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997; 350:261.

14 Isojarvi JI TJ Laatikainen Pakarinen AJ Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329:1383-8.

15 Johnson KC. ‘First trimester anticonvulsant therapy and the risk of congenital malformation in the offspring of women with epilepsy.’ PhD Thesis, Department of Epidemiology and Biostatistics, McGill University, Montreal, 1992.

16 Adab N A Jacoby Smith D Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001; 70:15-21.

17 Craig JJ Morrow JI. New antiepileptic drugs. Register of women who take the drugs during pregnancy has been set up. BMJ 1997; 314:603.

18Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41:617-8.

19 Lunn MP H Manji Choudhary PP Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999; 66:677-80.

20 Hadden RD Hughes RA. Treatment of immune-mediated inflammatory neuropathies. Curr Opin Neurol 1999; 12:573-9.

21 Azulay JP O Blin Pouget J Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994; 44:429-32.

22Van den Berg LH, Kerkhoff H, Oey PL Treatment of multifocal motor neuropathy with high dose intravenous immunogloblins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 59:248-52.

23 Dyck PJ KF Oviatt Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol 1981; 10:222-6.

24 Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540-5.

25 Hublin C J Kaprio Partinen M The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol 1994; 35:709-16.

26 Siegel JM. Narcolepsy: a key role for hypocretins (orexins). Cell 1999; 98:409-12.

27 Smith D BA Defalla Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM 1999; 92:15-23.

28 Lempert T M Bauer Schmidt D. Syncope: a videometric analysis of 56 episodes of transient cerebral hypoxia. Ann Neurol 1994; 36:233-7.

29 Rajput AH A Rajput Lang AE New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov Disord 1998; 13:851.

30Verhagen Metman L, Del Dotto P, van den Munckhof P Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 1998; 50:1323-6.

31 Swedo SE HL Leonard Garvey M Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155:264-71.